(ZYME) Zymeworks Common Stock - Ratings and Ratios

Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biotechnology company specializing in the discovery, development, and commercialization of next-generation biotherapeutics for cancer, autoimmune, and inflammatory diseases. The company leverages its proprietary therapeutic platforms and integrated drug development capabilities to engineer highly differentiated antibody-based treatments. These platforms include the Azymetric multispecific antibody platform, which enables the creation of bispecific and multispecific antibodies with tailored effector functions; the Drug Conjugate platform, featuring a suite of proprietary cytotoxins, stable linkers, and conjugation technologies to enhance the delivery of potent payloads to targeted tissues; the EFECT platform, which modifies the Fc region of antibodies to selectively modulate immune cell activity; and ProTECT, a tumor-specific immune co-stimulation platform designed to enhance anti-tumor immunity while minimizing systemic toxicity.

The companys lead product candidate, zanidatamab, is a novel bispecific antibody targeting HER2-expressing cancers. It is currently in multiple clinical trials, including Phase 1, Phase 2, and Phase 3 studies, with pivotal trials ongoing. Zanidatamab zovodotin, an HER2-targeted antibody-drug conjugate, is in Phase 2 clinical trials for advanced or metastatic HER2-expressing tumors. Zymeworks also maintains a robust preclinical pipeline focused on addressing unmet medical needs in oncology and inflammatory diseases. The company has established strategic partnerships with major pharmaceutical players, including BeiGene, GlaxoSmithKline, Daiichi Sankyo, and Merck, to advance its therapeutic candidates and expand its global reach.

Zymeworks Inc. was founded in 2003 and is headquartered in Middletown, Delaware. The company operates in the biotechnology sector and is listed on the NASDAQ exchange under the ticker symbol ZYME.